Get the Stockscreener App
3.52
0.00%
0.00
Pre-market:
3.55
0.03
+0.85%
Alzamend Neuro Inc stock is traded at $3.52, with a volume of 43,797.
It is up +0.00% in the last 24 hours and down -42.43% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$3.52
Open:
$3.53
24h Volume:
43,797
Relative Volume:
0.30
Market Cap:
$2.82M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.5263
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
-8.57%
1M Performance:
-42.43%
6M Performance:
-69.91%
1Y Performance:
-93.79%
1-Day Range:
$3.45
$3.55
1-Week Range:
$3.0558
$3.83
52-Week Range:
$3.0558
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
3.52 | 2.82M | 0 | -5.85M | -8.00M | -6.6877 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend begins phase II trial for novel lithium therapy - Investing.com Australia
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Alzheimer's Treatment | ALZN Stock News - GuruFocus
Alzamend Neuro Enrolls First Patient in its Phase II - GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study - marketscreener.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
Alzamend Neuro (ALZN) Begins Key Phase II Trials of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 'Lithium in Brain” Study Taking Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Alzamend Neuro to conduct reverse stock split - MSN
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com India
Alzamend Neuro Announces Reverse Stock Split Plan - TipRanks
Stock Market Recap: Alzamend Neuro Inc (ALZN) Concludes at 0.60, a -6.22 Surge/Decline - DWinneX
Alzamend Neuro (ALZN) Announces Reverse Stock Split | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Reverse Stock Split - The Manila Times
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements - Investing.com
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro partners with Mint Labs to support five upcoming trials - TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered - GlobeNewswire
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical ... - Eagle-Tribune
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program - Yahoo
Geode Capital Management LLC Buys New Stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Seeking Alpha
Alzamend Neuro, Inc.Common Stock (Nasdaq:ALZN) Stock Quote - FinancialContent
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 37.6% in April - Defense World
Form 8-KCurrent report - ADVFN
ALZN Stock Sees Decline of Approximately -12.99% in Last Five Days - knoxdaily.com
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia
Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times
Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com
Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India
Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK
Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India
Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa
Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq
Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire
Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):